Signatera™ for Sarcoma

Personalized, tumor-informed ctDNA molecular residual disease (MRD) testing to inform sarcoma patient care across all subtypes

Request Info

Better biomarkers are needed to help inform sarcoma patient management

Sarcoma is an aggressive cancer that is diagnosed in ~17,000 patients annually across over 70 distinct histological subtypes, with up to 40% of patients experiencing progression to metastatic disease.^1-3
Due to its heterogeneity, Sarcoma recurrence detection and treatment response monitoring can be challenging with standard imaging techniques and clinical assessment.

Signatera™’s clinical validation in the largest sarcoma ctDNA study to-date

A recent study conducted by Stanford University set out to determine if Signatera™ could help better detect recurrences and measure response to treatment⁴

The study assessed the correlation of Signatera™ results with imaging, stratified by sarcoma subtype, and followed patients through treatment, progression, and surveillance.
>2,000 samples were collected from 210 sarcoma patients across 5 tumor sites and >15 subtypes.

View Presentation

Detect recurrence early and monitor treatment response with Signatera™

Signatera™ detected sarcoma recurrence with 89% sensitivity and 100% specificity across tumor sites and subtypes

In leiomyosarcoma, the most common subtype in the cohort, sensitivity and specificity were 93% and 100% respectively, demonstrating a 95% ctDNA correlation.
For leiomyosarcoma patients who experienced progression, ctDNA dynamics during subsequent therapy were highly correlated with treatment response (90%).
All 16 patients who were serially Signatera™-negative remained recurrence free with a median follow-up of 22 months.

View Presentation

SGN_BA_SarcomaGraph_20250623_NAT-8022556-01

Is Signatera™ for Sarcoma right for your patients?

We’re here to help you find out

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹Moffitt Cancer Center. Moffitt Cancer Center. What are the different types of sarcoma? https://www.moffitt.org/cancers/sarcoma/faqs/what-are-the-different-types-of-sarcoma/. Accessed March 31, 2025.

²Sarcoma Alliance. (n.d.). What is sarcoma? Sarcoma Alliance. Retrieved April 28, 2025, from https://sarcomaalliance.org/what-is-sarcoma/.

³Spalato-Ceruso M, Ghazzi NE, Italiano A. New strategies in soft tissue sarcoma treatment. Journal of Hematology & Oncology. 2024;17:76. https://doi.org/10.1186/s13045-024-01580-3

⁴Sun B, et al. Using circulating tumor DNA to monitor sarcoma treatment and recurrence. Presented at the 2025 SSO Annual Meeting.